Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacotherapy for Behcet's syndrome.

A Saenz1, M Ausejo, B Shea

  • 1Clinical Epidemiology Unit-C406, Loeb Research Institute, Ottawa Hospital-Civic Site, 1053 Carling Avenue, Ottawa, Ontario, Canada, K1Y 4E9. BSHEA@LRI.CA

The Cochrane Database of Systematic Reviews
|May 5, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Constraints on General Neutrino Interactions Based on KATRIN Data.

Physical review letters·2025
Same author

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors.

Seminars in arthritis and rheumatism·2025
Same author

New Constraint on the Local Relic Neutrino Background Overdensity with the First KATRIN Data Runs.

Physical review letters·2022
Same author

The ASAS-OMERACT core domain set for axial spondyloarthritis.

Seminars in arthritis and rheumatism·2021
Same author

Bound on 3+1 Active-Sterile Neutrino Mixing from the First Four-Week Science Run of KATRIN.

Physical review letters·2021
Same author

Moving Towards Common Data Elements and Core Outcome Measures in Frailty Research.

The Journal of frailty & aging·2020

This review found that while some traditional treatments for Behcet's syndrome lack efficacy, cyclosporine, azathioprine, and benzathine-penicillin show promise for specific symptoms. Further research is needed to confirm these findings.

Area of Science:

  • Rheumatology
  • Immunology
  • Ophthalmology

Background:

  • Behcet's syndrome is a rare, chronic inflammatory disorder affecting multiple organ systems.
  • Current pharmacological treatments for Behcet's syndrome exhibit variable efficacy across its diverse clinical manifestations.

Purpose of the Study:

  • To evaluate the effectiveness of available pharmacological interventions for the various clinical features of Behcet's syndrome.
  • To synthesize evidence from randomized controlled trials on Behcet's syndrome treatments.

Main Methods:

  • A systematic search of major databases (Cochrane, Medline) was conducted up to January 1998.
  • Ten randomized controlled trials meeting strict inclusion criteria were analyzed.
  • Data extraction and quality assessment were performed independently by two reviewers.

Related Experiment Videos

Main Results:

  • Colchicine, cyclophosphamide, and steroids were found ineffective for ocular inflammation in Behcet's syndrome.
  • Azapropazone and colchicine showed no efficacy for arthritis; acyclovir, colchicine, and topical interferon were ineffective for aphthas.
  • Cyclosporine and azathioprine demonstrated protective effects for ocular involvement, and benzathine-penicillin for arthritis.

Conclusions:

  • Cyclosporine, azathioprine, and benzathine-penicillin show potential for treating specific Behcet's syndrome manifestations.
  • Further high-quality, placebo-controlled trials are recommended to establish definitive treatment guidelines.
  • Standardized trial designs are necessary for comparable and generalizable results in Behcet's syndrome research.